Celcuity Inc (CELC) News

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call 

MINNEAPOLIS, March 24, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology...

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 PR Newswire VANCOUVER, BC, Feb. 27, 2025 USA...

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025

Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 PR Newswire VANCOUVER, BC, Feb. 27, 2025 USA...

Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences

MINNEAPOLIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology...

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium

Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 4 - Statement of changes in beneficial ownership of securities

Form EFFECT - Notice of Effectiveness

Form S-3/A - Registration statement under Securities Act of 1933: [Amend]

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]